IX Biopharma's Sublingual NAD+ Wafers Show Promising Results in Human Trial
IX Biopharma's Sublingual NAD+ Wafers Show Promising Results in Human Trial
ix生物制药的舌下NAD+片剂在人体试验中表现出良好的结果
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册